These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 1389521)

  • 21. Adjuvant chemotherapy in operable breast cancer: cyclophosphamide, methotrexate, and fluorouracil versus chlorambucil, methotrexate, and fluorouracil--11-year results of Swiss Group for Clinical Cancer Research trial SAKK 27/82.
    Senn HJ; Maibach R; Castiglione M; Jungi WF; Cavalli F; Leyvraz S; Obrecht JP; Schildknecht O; Siegenthaler P
    J Clin Oncol; 1997 Jul; 15(7):2502-9. PubMed ID: 9215818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.
    Rivkin SE; Green S; Metch B; Glucksberg H; Gad-el-Mawla N; Constanzi JJ; Hoogstraten B; Athens J; Maloney T; Osborne CK
    J Clin Oncol; 1989 Sep; 7(9):1229-38. PubMed ID: 2671283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collaborative Cancer Group.
    Coombes RC; Bliss JM; Wils J; Morvan F; Espié M; Amadori D; Gambrosier P; Richards M; Aapro M; Villar-Grimalt A; McArdle C; Pérez-López FR; Vassilopoulos P; Ferreira EP; Chilvers CE; Coombes G; Woods EM; Marty M
    J Clin Oncol; 1996 Jan; 14(1):35-45. PubMed ID: 8558217
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as adjuvant chemotherapy in breast cancer.
    Livi L; Saieva C; Borghesi S; De Luca Cardillo C; Scotti V; Mangoni M; Greto D; Cataliotti L; Paiar F; Bianchi S; Biti GP
    J Chemother; 2009 Nov; 21(5):558-65. PubMed ID: 19933048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controlled trial of adjuvant chemotherapy with cyclophosphamide, methotrexate, and fluorouracil for breast cancer.
    Howell A; Bush H; George WD; Howat JM; Crowther D; Sellwood RA; Rubens RD; Hayward JL; Bulbrook RD; Fentiman IS
    Lancet; 1984 Aug; 2(8398):307-11. PubMed ID: 6146861
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of the outcomes of non-randomised chemotherapy regimens in node positive breast cancer.
    Kuru B; Camlibel M; Dinc S; Gulcelik MA; Atalay C; Alagol H
    J Exp Clin Cancer Res; 2005 Sep; 24(3):363-72. PubMed ID: 16270522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized trial on the effect of radiotherapy in addition to 6 cycles CMF in node-positive breast-cancer patients. The German Breast-Cancer Study Group.
    Schmoor C; Bastert G; Dunst J; Bojar H; Christmann D; Unbehaun V; Tümmers G; Bauer W; Sauerbrei W; Schumacher M
    Int J Cancer; 2000 May; 86(3):408-15. PubMed ID: 10760830
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of c-erbB(2) and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/methotrexate/fluorouracil.
    Miles DW; Harris WH; Gillett CE; Smith P; Barnes DM
    Int J Cancer; 1999 Aug; 84(4):354-9. PubMed ID: 10404085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Local recurrence after mastectomy and adjuvant CMF: implications for adjuvant radiation therapy.
    Rangan AM; Ahern V; Yip D; Boyages J
    Aust N Z J Surg; 2000 Sep; 70(9):649-55. PubMed ID: 10976894
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ten-year results of a randomized trial evaluating prolonged low-dose adjuvant chemotherapy in node-positive breast cancer: a joint European Organization for Research and Treatment of Cancer-Dutch Breast Cancer Working Party Study. Cooperating Investigators.
    Clahsen PC; van de Velde CJ; Welvaart K; van Driel OJ; Sylvester RJ
    J Clin Oncol; 1995 Jan; 13(1):33-41. PubMed ID: 7799039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
    Battelli N; Massacesi C; Braconi C; Pilone A; Manzione L; Dinota A; Cobelli S; Scanni A; Sturba F; Giacomini G; Morale D; Giorgi F; Tummarello D; Cascinu S
    Am J Clin Oncol; 2006 Aug; 29(4):380-4. PubMed ID: 16891866
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
    Buzzoni R; Bonadonna G; Valagussa P; Zambetti M
    J Clin Oncol; 1991 Dec; 9(12):2134-40. PubMed ID: 1960555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement.
    Ung O; Langlands AO; Barraclough B; Boyages J
    J Clin Oncol; 1995 Feb; 13(2):435-43. PubMed ID: 7844606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant chemotherapy with cyclophosphamide or CMF in premenopausal women with stage II breast cancer.
    Brincker H; Mouridsen HT; Andersen KW
    Breast Cancer Res Treat; 1983; 3(1):91-5. PubMed ID: 6347278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI.
    Gruber G; Bonetti M; Nasi ML; Price KN; Castiglione-Gertsch M; Rudenstam CM; Holmberg SB; Lindtner J; Golouh R; Collins J; Crivellari D; Carbone A; Thürlimann B; Simoncini E; Fey MF; Gelber RD; Coates AS; Goldhirsch A;
    J Clin Oncol; 2005 Oct; 23(28):7089-97. PubMed ID: 16192592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant sequential chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil (ACMF) with concurrent radiotherapy in resectable advanced breast cancer.
    Hsieh CI; Liu MC; Cheng SH; Liu TW; Chen CM; Chen CM; Tsou MH; Huang AT
    Am J Clin Oncol; 2000 Apr; 23(2):122-7. PubMed ID: 10776970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen.
    Isaac N; Panzarella T; Lau A; Mayers C; Kirkbride P; Tannock IF; Vallis KA
    Cancer; 2002 Aug; 95(4):696-703. PubMed ID: 12209711
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
    Ejlertsen B; Mouridsen HT; Jensen MB
    Acta Oncol; 2008; 47(4):662-71. PubMed ID: 18465334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Breast cancer recurrence dynamics following adjuvant CMF is consistent with tumor dormancy and mastectomy-driven acceleration of the metastatic process.
    Demicheli R; Miceli R; Moliterni A; Zambetti M; Hrushesky WJ; Retsky MW; Valagussa P; Bonadonna G
    Ann Oncol; 2005 Sep; 16(9):1449-57. PubMed ID: 15956037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.